IM Cannabis Corp. has announced its financial results for the third quarter of 2026, revealing a challenging period for the company. The report highlights a significant drop in revenue and an increase in net losses, reflecting the ongoing struggles in the medicinal cannabis industry.
For the three months ending September 30, 2026, IM Cannabis reported revenue of $1.65 million, down from $5.08 million in the same period last year. The company also faced a gross loss of $0.04 million compared to a gross profit of $1.58 million in Q3 2025. The net loss for this quarter was $7.08 million, or $6.69 per share, compared to a net loss of $3.87 million, or $0.44 per share, in the prior year.
IM Cannabis Corp. is a company focused on the medicinal cannabis sector, operating primarily in Israel. The company has been navigating a challenging market, which has affected its financial performance. The latest filing, dated November 13, 2026, provides a comprehensive overview of the company's financial statements and management's discussion regarding its operations.
Background
IM Cannabis Corp. is classified under the SIC code 2833, which pertains to Medicinal Chemicals & Botanical Products. The company operates on the Nasdaq under the ticker IMCC. It has been involved in the medical cannabis sector, providing products and services to patients in Israel.
Recent filings indicate that IM Cannabis has been active in various financial maneuvers, including the sale of I.M.C. Holdings Ltd., which was completed on September 28, 2026. This sale has restructured the company’s operations, focusing on its core business in Israel while divesting from European operations.
What the Filing Says
The filing includes several key components: unaudited interim condensed consolidated financial statements for the nine months ended September 30, 2026, management's discussion and analysis, and a press release detailing the financial results. The company reported a revenue from continuing operations of $8.96 million for the nine months ended September 30, down from $15.77 million in the same period in 2025.
Additionally, the gross profit for the nine months was $1.33 million, a decrease from $4.87 million in 2025. The net loss for the nine-month period was $13.93 million, compared to a net loss of $3.88 million in the same timeframe the previous year.
Impact
The financial results may affect various stakeholders, including investors, employees, and patients relying on IM Cannabis for medicinal products. The significant decline in revenue and increased losses could lead to heightened scrutiny from investors and potential challenges in securing future funding.
As the medicinal cannabis industry continues to evolve, IM Cannabis's struggles may resonate with other companies in the sector. Competitors may also be facing similar challenges, as the market adapts to regulatory changes and shifts in consumer demand.
What's Next
The filing does not specify what happens next for IM Cannabis Corp. However, the company is likely to continue focusing on its core operations in Israel while exploring potential growth opportunities, including the proposed acquisition of Space Defense Innovations, which was announced earlier this year.
Overall, IM Cannabis Corp.'s latest financial results underscore the complexities and difficulties faced by companies in the medicinal cannabis space, as they navigate a rapidly changing market landscape.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










